What it is
Vilon is a natural dipeptide — a peptide of just two amino acids, which makes it about as small as a peptide can be — isolated from the thymus gland. The thymus sits behind the breastbone and is where T-cells, the immune system's specialist recognition cells, are trained.
Its described roles are immune modulation, tissue regeneration, and cellular homeostasis — the balance a cell maintains to keep working properly.
As for the bioregulator class it belongs to: these are peptides, but far shorter than most on this site, and the brevity has a practical benefit. A smaller molecule gives the immune system less to recognise as foreign, so the risk of an unwanted immune reaction is lower.
They also act at a different level. A conventional peptide sends a signal to a cell from the outside, and when it clears, the signal stops. A bioregulator is matched to one tissue, enters the cells of that tissue, binds to DNA, and alters which genes are switched on or off. The genes involved are those controlling repair, regeneration, and ageing, which is why bioregulator effects are described as more foundational and longer-lasting than those of a standard peptide.
It comes as a dry powder in a 20 milligram vial, mixed with bacteriostatic water. Unlike most of the bioregulators on this site, Vilon can be given either by injection under the skin (subcutaneous) or injection into muscle (intramuscular).
Vilon is a naturally derived dipeptide isolated from the thymus gland, with stated roles in immune modulation, tissue regeneration, and cellular homeostasis.
Two amino acids is the floor for a peptide, and it makes Vilon the extreme case of the class argument made for bioregulators. That argument holds that brevity is protective — the shorter the chain, the less there is for the immune system to recognise as foreign — so a dipeptide should provoke less than anything else on this site. Brevity is also offered as what lets these compounds work from inside a cell rather than at its surface: the claim is DNA binding and regulation of which genes a cell in the target tissue expresses, against a conventional peptide that signals from outside and stops signalling once cleared. The persistence claim rests on which genes those are — repair, regeneration, and longevity — and so on effects that are meant to hold after the course ends. No specific gene has been named and no binding data is available — notable given that Vilon is the shortest compound to which the argument is applied.
Two features distinguish Vilon from the other bioregulators here. It permits either subcutaneous or intramuscular administration, where most specify subcutaneous alone. And its dose is the highest per administration of the 20 mg bioregulators on this site at 5 mg — two and a half times the 2 mg that most of them use — over the shortest course, 10 days.
The adverse effect list carries a qualifier worth noting: the effects are stated to be largely dependent on dose, frequency, and route of administration, which is a more careful framing than the flat lists on its sibling pages, and relevant given that the route here is genuinely optional.
Presentation: 20 mg lyophilised vial reconstituted with bacteriostatic water, 10-day courses repeated 3–4 times per year.
What it does
The primary strand is immune. It enhances the activity of T-cells — the white blood cells that recognise specific threats — and regulates immune responses generally. It helps restore balance where the immune system is deficient or has declined with age, and is used to normalise immune surveillance, the constant patrol for infected or abnormal cells.
The second strand is repair. It stimulates repair processes in damaged tissue, including skin, connective tissue, and internal organs, and it accelerates wound healing and recovery after injury or surgery.
The third is ageing. It slows age-related change by supporting genomic stability — DNA staying intact and accurate as cells divide — and by regulating epigenetic expression, which is the layer of control determining which genes a cell actually uses. It protects cells from oxidative stress, the damage caused by reactive molecules accumulating, and from apoptosis, meaning programmed cell death. It also helps maintain overall vitality and cell function.
Beyond that, it is used to provide recovery support for people undergoing or recovering from cancer treatment, and it is under investigation for neurodegenerative disorders such as Alzheimer's and Parkinson's.
Immune: enhanced T-cell activity with regulation of immune responses; restoration of balance in immunodeficiency and age-related immune decline; normalisation of immune surveillance.
Regenerative: stimulation of repair processes in damaged tissue including skin, connective tissue, and internal organs; accelerated wound healing and recovery after trauma or surgery.
Geroprotective: slowed age-related change through support of genomic stability and regulation of epigenetic expression; protection of cells from oxidative stress and apoptosis; maintenance of overall vitality and cellular function.
Oncological and neurological: recovery support for patients undergoing or recovering from cancer treatment; investigation in neurodegenerative disorders including Alzheimer's and Parkinson's disease.
Note the framing difference against Crystagen, the site's other thymus-derived bioregulator. Crystagen describes bidirectional normalisation — correcting both underactive and overactive immune states — and carries a substantial contraindication list built around that. Vilon describes enhancement of T-cell activity with regulation of responses, and carries no contraindication list at all. Whether that reflects a real difference in pharmacology or only a gap in the available data cannot be determined, and the absence of exclusions here should not be read as a cleaner profile. See the avoidance section.
The cancer-recovery positioning also warrants attention: it is stated without any of the active-malignancy qualifications that appear on the sibling bioregulator pages here.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Enhances T-cell activity and regulates immune responses.Animal or lab only
- Helps restore balance where the immune system is deficient or has declined with age.Animal or lab only
- Slows age-related change by supporting genomic stability and regulating which genes a cell actually uses.Animal or lab only
- Protects cells from oxidative stress and from programmed cell death.Animal or lab only
- Stimulates repair processes in damaged tissue, including skin, connective tissue, and internal organs.Animal or lab only
- Helps maintain overall vitality and cell function.Anecdotal
- Used to normalise immune surveillance — the constant patrol for infected or abnormal cells.Animal or lab only
- Provides recovery support for people undergoing or recovering from cancer treatment.Anecdotal
- Accelerates wound healing and recovery after injury or surgery.Animal or lab only
- Under investigation for neurodegenerative disorders such as Alzheimer's and Parkinson's.Anecdotal
- Enhances T-cell activity and regulates immune responses.Animal or lab only
- Restores balance in immunodeficiency and age-related immune decline.Animal or lab only
- Slows age-related change through genomic stability support and regulation of epigenetic expression.Animal or lab only
- Protects cells from oxidative stress and apoptosis.Animal or lab only
- Stimulates repair processes in damaged tissue including skin, connective tissue, and internal organs.Animal or lab only
- Maintains overall vitality and cellular function.Anecdotal
- Normalises immune surveillance.Animal or lab only
- Recovery support for patients undergoing or recovering from cancer treatment — stated without the active-malignancy qualification that appears on sibling bioregulator pages here.Anecdotal
- Accelerates wound healing and recovery after trauma or surgery.Animal or lab only
- Under investigation for neurodegenerative disorders including Alzheimer's and Parkinson's.Anecdotal
Reconstitution and dosing
The vial holds 20 milligrams (mg). Mix it with 2 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 200 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake.
With 20 mg in 2 mL, every unit on the syringe holds 100 micrograms. So 5 milligrams is 50 units.
There is one protocol and one dose: 5 milligrams a day for 10 days, with no ramp up or down. Repeat the cycle three to four times a year.
Either injection under the skin or injection into muscle is allowed, with no stated preference. Most of the bioregulators on this site specify only under the skin. Injection into muscle uses a longer needle and is generally more uncomfortable.
Notice the size of this dose. Fifty units is half the syringe, and it is two and a half times the daily dose most of the other 20 mg bioregulators on this site use. The course is also the shortest of them, at 10 days. A whole 10-day course uses 50 milligrams — two and a half vials — so you will open a second vial partway through.
No time of day for dosing has been specified, and there is no guidance on food.
Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL — 100 mcg per insulin unit. Add down the vial wall and swirl; do not shake.
Draw: 5 mg = 50 units.
Administration: subcutaneous or intramuscular, either permitted without a stated preference. That is unusual among the bioregulators on this site, most of which specify subcutaneous alone, and it interacts with the stated qualification that adverse effects depend partly on route — without the two being differentiated.
Protocol: flat 5 mg daily for 10 days, no titration. Repeated 3–4 times per year.
Dose context: at 5 mg this is the highest per-administration dose among the 20 mg bioregulators on this site, 2.5× the 2 mg used by most of them, over the shortest course at 10 days. Cumulative exposure is 50 mg per cycle — two and a half vials, so a second vial is opened mid-course — and 150–200 mg per year at 3–4 cycles. A 50-unit subcutaneous injection is also a substantial volume for the route, which is one plausible reason the intramuscular option is offered, though this has not been stated.
No dosing time and no meal relationship are stated.
20 mg vial
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit. A 10-day course uses 50 mg, i.e. two and a half vials.
10 mg/mL · 100 mcg per unit
Cycle: 10-day cycle; repeat 3–4 times per year · Frequency: 1×/day, daily; subcutaneous or intramuscular. No dosing time or relationship to meals has been specified
| When | Dose | Draw | How often |
|---|---|---|---|
| Days 1–10 (5 mg) | 5 mg | 50 units | 1×/day |
20 mg in 2 mL is 10 mg/mL, or 100 mcg per unit. Draw 50 units (0.5 mL) for 5000 mcg.
Who should avoid it
- No exclusions have been documented, and there is no contraindications list at all. Treat that as missing information rather than as clearance for everyone — and note that Crystagen, the other thymus-derived bioregulator on this site, has a long list of exclusions for a compound doing much the same thing.
- Carried from the Crystagen page on this site, because the two act on the same tissue and in much the same way: take great care if you have an autoimmune condition such as lupus, rheumatoid arthritis, or multiple sclerosis, since altering immune function could in theory make those worse; take care if you are on medicines that deliberately suppress the immune system, or have had an organ transplant, because the result may be unpredictable; and take care with an acute infection or sepsis, where the body's reaction may be unpredictable.
- Two things are known to add to Vilon's effects: Thymosin Alpha-1 or Thymogen, and **interferons** — signalling proteins the immune system uses, also given as medicines. These are presented as additive effects rather than as warnings, but adding to an immune effect is the thing the cautions above are about.
- One interaction comes from another page. The Pancragen page on this site names Vilon specifically, saying that combining the two may temporarily heighten immune sensitivity.
- Pregnancy, breastfeeding, and use in anyone under 18 are not addressed either way. Every other bioregulator page on this site excludes all three.
- The other bioregulator pages here all exclude anyone who has reacted badly to a peptide product before, and that caution reasonably applies.
- Talk to a doctor before starting, and go through your full medication list with them.
- No contraindication list has been established. Read that as absent documentation, and read it specifically against Crystagen — the site's other thymus-derived bioregulator — whose page carries exclusions for pregnancy, peptide hypersensitivity, late-stage renal or hepatic failure, active malignancy, autoimmune disease, immunosuppression and transplantation, and acute infection or sepsis. Nothing in the available data distinguishes the two pharmacologically.
- Carried from the Crystagen page on this site on shared thymus-derived immunomodulatory grounds: autoimmune conditions — lupus, rheumatoid arthritis, multiple sclerosis named there — with theoretical exacerbation through immune modulation; immunosuppressant therapy or organ transplantation, with unforeseen results stated as the risk; acute infection or sepsis, with unpredictable host response.
- Documented as additive rather than as caution: Thymosin Alpha-1 or Thymogen, and interferons. Additive immunological effect is the substance of the cautions above, so the framing difference is presentational rather than pharmacological.
- Cross-referenced from the Pancragen page on this site, which names Vilon explicitly: combination may temporarily heighten immune sensitivity.
- Pregnancy, lactation, and paediatric use are unaddressed. Every other bioregulator page here excludes all three.
- Peptide hypersensitivity, the standard class exclusion on the sibling pages, is not addressed.
- The cancer-recovery indication carries no active-malignancy qualification, where both Crystagen and Prostamax on this site require physician clearance or advise against use during active disease.
Side effects
- These effects depend largely on the dose, how often you take it, and how you administer it. That last point matters here, because the route is genuinely a choice on this page — under the skin or into muscle.
- Reactions where you inject — redness, swelling, or itching.
- Headache.
- Stomach and gut upset — nausea, abdominal pain, or indigestion.
- Temporary flushing, or a feeling of warmth in the skin.
- No monitoring is suggested, and nothing is said about when to stop.
- No explanation is available for the flushing or the stomach upset.
- The list is qualified as largely dependent on dose, frequency, and route of administration — a more careful framing than the flat lists on sibling pages here, and materially relevant given that the route is optional on this page and the per-dose amount is the highest of the 20 mg bioregulators on this site.
- Injection site reactions: erythema, swelling, and/or pruritus.
- Headache.
- Gastrointestinal upset: nausea, abdominal pain, indigestion.
- Transient flushing or cutaneous warmth.
- No mechanism is available for the flushing or gastrointestinal items, and no differentiation is given between the subcutaneous and intramuscular profiles despite the route being explicitly variable.
- No monitoring parameters or discontinuation criteria have been established.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Known to have additive effects with Vilon. Both come from the thymus and both act on the immune system, so the effects build on each other. That is presented as a fact rather than a warning, but it is still two immune-acting compounds at once.
Documented as producing additive effects. Both are thymus-derived immunomodulators, so the additivity is unsurprising and the relevant consideration is total immunological load — particularly against the Crystagen-derived cautions carried onto this page. The Pancragen entry on this site separately lists both compounds as raising immune sensitivity in combination with it.
- Thymogen
Named alongside Thymosin Alpha-1 as having additive effects with Vilon. There is no page for it on this site, and no dosing guidance for the combination is available.
Named alongside Thymosin Alpha-1 in the additive effects list. No page exists for it on this site and no combined schedule or monitoring guidance is offered.
- Interferons
The third thing documented as additive. Interferons are signalling proteins the immune system makes, and are also given as prescription medicines for some infections and cancers. If you are prescribed one, this is a conversation for the prescriber rather than something to combine on your own.
Named in the additive effects list. Interferons are prescriber-managed agents in hepatitis, multiple sclerosis, and certain malignancies, so this is a clinical interaction rather than a stack — and an additive immunological effect on top of prescribed interferon therapy is exactly the scenario the borrowed immunosuppression and autoimmune cautions bear on.
Not a suggested stack. Listed because Crystagen is the other thymus-derived bioregulator on this site and is where the warnings above are carried from — its page has the exclusions this one lacks. Using both together means doubling up on immune modulation, which is the thing those warnings caution against.
Not a suggested stack; listed as the nearest neighbour and the origin of the contraindications carried onto this page. Overlapping thymus-derived immunomodulation makes concurrent use additive on the axis both pages act on, and Crystagen's exclusions — autoimmune disease, immunosuppression, acute infection, active malignancy — govern the combination.
Dosing figures have been reviewed and units are recomputed from the stated protocol.